Organisation paid for research Program year 2025 Source: CMS Open Payments

Comprehensive Cancer Centers

Neither a doctor nor a teaching hospital

Research payments

$1,708,891

60 payments

Through program year 2025, Comprehensive Cancer Centers is reported as receiving $1,708,891 in research payments, across 60 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $21,260 1
2023 Research $13,600 1
2022 Research $723,611 16
2021 Research $709,858 24
2020 Research $240,562 18

Breakdown

Who paid Research payments · program years 2020–2025
  1. BeiGene, Ltd. $808,024 25 payments
  2. AstraZeneca Pharmaceuticals LP $418,453 13 payments
  3. AstraZeneca UK Limited $369,782 4 payments
  4. Pfizer Inc. $76,104 1 payment
  5. Coherus Biosciences Inc. $34,860 2 payments
  6. Pharmacyclics LLC, An AbbVie Company $1,373 4 payments
  7. Secura Bio, Inc. $295 11 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib $808,024 25 payments
  2. This is a modular, phase 2a, open-label, multicentre study of DDR agents (or combinations), administered to participants with advanced/metastatic solid and/or haematological malignancies with molecular alterations $230,688 2 payments
  3. A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA 1) $183,808 4 payments
  4. A Phase 3 Randomized Double-blind Multicenter Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor $158,456 3 payments
  5. iMED Oncology project- Sarah Cannon Research Institute Agreemet $139,094 2 payments
  6. A Phase 1 Dose Escalation and Expansion Study Evaluating Safety Tolerability and Pharmacokinetics of PF 06952229 in Adult Patients With Advanced Solid Tumors $76,104 1 payment
  7. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) $41,842 2 payments
  8. Chs11402 $21,260 1 payment
  9. Chs601 $13,600 1 payment
  10. A Phase 2, Open-label, Randomized, Multicenter, Platform Study of Novel Oncology Therapies in Combination with Adjuvant Chemotherapy in High-risk Microsatellite-stable Colorectal Cancer (COLUMBIA-2) $13,450 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record